Proteome Sciences PLC Appointment of Richard Dennis as CCO (2561B)

TIDMPRM

RNS Number : 2561B

Proteome Sciences PLC

03 April 2017

Proteome Sciences plc

(the "Company" or the "Group")

Appointment of Richard Dennis as Chief Commercial Officer

The Company is pleased to confirm that Richard Dennis has joined us as Chief Commercial Officer, the first person to hold such a role at Proteome Sciences. Richard brings over 30 years' experience of strategic sales and marketing, combined with significant technical knowledge, gained most recently as Director of International Commercial Operations at Quanterix Corp. where he was instrumental in establishing successful sales organisations in Europe, Japan and China. Previously he had held positions of increasing commercial responsibility at Bioscale Inc. and Meso Scale Discovery.

Richard Dennis commented: "I have been involved with proteins throughout my commercial career and am excited to be joining Proteome Sciences at this time. Never has the 'power of the protein' been better understood by, and more important to, the scientific community. Proteome Sciences can fully exploit this potential and I look forward to leading the commercial team to achieve this."

Jeremy Haigh, Chief Executive Officer, commented: "Given the critical importance of commercialising our biomarker services to the future success of Proteome Sciences, I am delighted to welcome Richard Dennis to the Company as our first Chief Commercial Officer. His experience of building successful sales organisations across the world makes him a hugely valuable addition to the Company and I look forward to working with him as he executes a commercial plan for the services business and provides integrated commercial leadership for the Company."

 
 For further information: 
 
  Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive Officer Tel: 
  +44 (0)1932 865065 
 Dr Ian Pike, Chief Scientific 
  Officer 
 Geoff Ellis, Finance Director 
 
   finnCap Limited (Nominated 
   Adviser/Broker)                            Tel: +44 (0)20 7220 
   Geoff Nash/James Thompson                  0500 
 Tony Quirke (broking) 
 
  IFC Advisory (Financial PR and IR) 
 Tim Metcalfe/Graham                        Tel: +44 (0)20 3053 
  Herring/Miles Nolan                        8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSDIFMFFWSEED

(END) Dow Jones Newswires

April 03, 2017 02:00 ET (06:00 GMT)

Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024